logo
Plus   Neg
Share
Email

Lufthansa Comments On 2020 Outlook; 2019 Net Profit Declines - Quick Facts

Lufthansa AG (DLAKF,DLAKY) said, for fiscal 2020, the magnitude of the expected decline in adjusted EBIT is currently not predictable. The Lufthansa Executive Board has decided to waive 20 percent of its basic remuneration in 2020. To counter Corona crisis, the company plans comprehensive savings measures including: far-reaching capacity reductions, "short-time working" mechanism in home markets and suspension of dividend.

Carsten Spohr, Chairman of the Executive Board, said: "We have to counter this extraordinary situation with drastic and sometimes painful measures. The longer this crisis lasts, the more likely it is that the future of aviation cannot be guaranteed without state aid."

For fiscal 2019, Lufthansa reported that its consolidated net profit declined 44 percent to 1.2 billion euros. Adjusted EBIT margin was 5.6 percent compared to 8.0 percent. Adjusted EBIT was at 2.0 billion euros. The company said the main drivers for the decline were a 600 million euro increase in fuel costs and a noticeable economic slowdown, especially in home markets.

Fiscal 2019 revenue rose by 2.5 percent to 36.4 billion euros. Unit revenues of the passenger airlines declined by 2.5 percent, adjusted for exchange rate effects.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT